Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR study

Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR study

Background: Tezepelumab, a human monoclonal antibody, blocks the activity of thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced exacerbations by 56% compared with placebo in adults and adolescents with severe, uncontrolled asthma. This analysis evaluated...

Full description

Bibliographic Details
Main Authors: Tamotsu Ishizuka, Andrew Menzies-Gow, Hiroshi Okada, Yasushi Fukushima, Nobuya Hayashi, Gene Colice, Sandhia Ponnarambil, Gillian Hunter, Hiroshi Odajima, Motohiro Ebisawa
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Allergology International
Subjects:
Biologic
Randomized controlled trial
Severe asthma
Thymic stromal lymphopoietin
TSLP
Online Access:http://www.sciencedirect.com/science/article/pii/S132389302200082X

Internet

http://www.sciencedirect.com/science/article/pii/S132389302200082X

Similar Items